Maxim lowered the firm’s price target on Nutex Health (NUTX) to $205 from $225 and keeps a Buy rating on the shares. On August 14th, the company filed an NT 10-Q notification of inability to timely file its 10-Q for the three months ended 6/30/25, due to the incorrect accounting classification of certain non-cash obligations, the analyst tells investors in a research note. The firm views the accounting restatements, arbitration dynamics, and lawsuits against Nutex’s primary arbitration vendor, HaloMD, as potential headwinds to the stock price, Maxim added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUTX: